At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Apr 30, 2026 at 08:30 ET
OPKO Health announced an amendment to its Nicoya Therapeutics agreement, receiving a 15% equity stake in Nicoya in exchange for revised royalty/transfer pricing, while keeping the $115M milestone structure intact. The deal deepens strategic alignment for RAYALDEE commercialization in Greater China, where regulatory approvals are expected in 2027, but provides no immediate revenue or cash consideration.
- OPKO received a 15% equity stake in Nicoya via Series A-2 Preferred Shares in two tranches.
- Revised tiered royalty and transfer price schedule replaces prior terms; milestone payments up to $115M unchanged.
- RAYALDEE approved in Macau; regulatory approvals in China and related territories expected in 2027.
- No upfront cash payment or immediate revenue recognized from the amendment.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access